- Analytica (ALT) has placed its shares in a trading halt for the purpose of an upcoming capital raising
- The company will remain in the halt until the earlier of April 23 or when a more detailed announcement is made
- Just yesterday, Analytica entered a 10-year agreement with Egyptian company Marwa’s Office for Export and Import Medical Supplies
- The agreement will see Marwa distribute and market Analytica’s Enhance Infusion System (EIS) across countries such as Egypt, Saudi Arabia and the UAE
- The EIS is a simple and inexpensive solution that regulates monitoring and refilling of burettes in intravenous fluid infusions
- It automatically starts IV fluid and delivers an uninterrupted flow and can operate without continuous monitoring
- Shares in Analytica last traded at 0.5 cents on April 20
Analytica (ALT) has placed its shares in a trading halt for the purpose of an upcoming capital raising.
The company will remain in the halt until the earlier of April 23 or when a more detailed announcement is made.
Analytica is yet to disclose how much it intends to raise or what it will be using the funds for once received.
Just yesterday, Analytica entered an agreement with Egyptian company Marwa’s Office for Export & Import Medical Supplies for the distribution and marketing of Enhanced Infusion System (EIS).
This agreement will see EIS be distributed across Egypt, Jordan, Iran, Bahrain, Iraq, Saudi Arabia, Lebanon, Kuwait and the United Arab Emirates.
The EIS is a simple and inexpensive solution that regulates monitoring and refilling of burettes in intravenous fluid infusions.
It automatically starts IV fluid and delivers an uninterrupted flow and can operate without continuous monitoring.
This agreement allows Analytica to bring its technology into global markets and build new partnerships.
The agreement will run for 10 years unless it is terminated earlier.
Shares in Analytica last traded at 0.5 cents on April 20. The company has a $17.59 million market cap.